Subject(s)
COVID-19/physiopathology , Cerebrovascular Disorders/physiopathology , Cognitive Dysfunction/physiopathology , Deglutition Disorders/physiopathology , Dysphonia/physiopathology , Executive Function , Adult , Angiography, Digital Subtraction , Basal Ganglia/diagnostic imaging , COVID-19/diagnostic imaging , Cerebral Angiography , Cerebrovascular Disorders/diagnostic imaging , Cerebrovascular Disorders/drug therapy , Diffusion Magnetic Resonance Imaging , Emergency Service, Hospital , Glucocorticoids/therapeutic use , Humans , Immunoglobulins, Intravenous/therapeutic use , Immunologic Factors/therapeutic use , Magnetic Resonance Imaging , Male , Methylprednisolone/therapeutic use , Patient Discharge , Pons/diagnostic imaging , Posterior Cerebral Artery/diagnostic imaging , SARS-CoV-2 , Severity of Illness Index , Thalamus/diagnostic imaging , Tomography, X-Ray Computed , White Matter/diagnostic imaging , COVID-19 Drug TreatmentSubject(s)
COVID-19/complications , Guillain-Barre Syndrome/diagnosis , Antiviral Agents/therapeutic use , Bradycardia/physiopathology , COVID-19/diagnosis , COVID-19/therapy , Deglutition Disorders/physiopathology , Diagnosis, Differential , Dysphonia/physiopathology , Facial Nerve Diseases/physiopathology , Gastroparesis/physiopathology , Guillain-Barre Syndrome/etiology , Guillain-Barre Syndrome/physiopathology , Humans , Hypertension/physiopathology , Hypoglossal Nerve Diseases/physiopathology , Male , Middle Aged , Muscle Weakness/physiopathology , Neck Muscles/physiopathology , Polyneuropathies/diagnosis , Respiration, Artificial , Respiratory Insufficiency/therapy , Tachycardia/physiopathology , Upper ExtremityABSTRACT
The ongoing pandemic of Coronavirus disease 2019 (COVID-19) has infected more than 27 million confirmed cases and 8,90,000 deaths all around the world. Verity of viral infections can infect the nervous system; these viral infections can present a wide range of manifestation. The aim of the current study was to systematically review the COVID-19 associated central nervous system manifestations, mental and neurological symptoms. For that we conducted a comprehensive systematic literature review of four online databases, including Web of Science, PubMed, Scopus and Embase. All relevant articles that reported psychiatric/psychological symptoms or disorders in COVID-19 without considering time and language restrictions were assessed. All the study procedures were performed based on the PRISMA criteria. Due to the screening, 14 studies were included. The current study result indicated that, the pooled prevalence of CNS or mental associated disorders with 95% CI was 50.68% (6.68-93.88). The most prevalence symptoms were hyposmia/anosmia/olfactory dysfunction (number of study: 10) with 36.20% (14.99-60.51). Only one study reported numbness/paresthesia and dysphonia. Pooled prevalence of numbness/paresthesia and dysphonia was 5.83% (2.17-12.25) and 2.39% (10.75-14.22). The pooled prevalence of depression and anxiety was 3.52% (2.62-4.54) and 13.92% (9.44-19.08). Our findings demonstrate that COVID-19 has a certain relation with neurological symptoms. The hypsomia, anosmia or olfactory dysfunction was most frequent symptom. Other symptoms were headache or dizziness, dysgeusia or ageusia, dysphonia and fatigue. Depression, anxiety, and confusion were less frequent symptoms.